TerSera Therapeutics LLC announces that it has completed the previously announced sale of its Infusion Specialty Therapies Business Unit (IST), including two specialty medications, Prialt® (ziconotide intrathecal infusion) and Quzyttir® (cetirizine hydrochloride injection) to ESTEVE.
Read the full article: TerSera Therapeutics Announces Closing of Divestiture of Infusion Specialty Therapies Business Unit to ESTEVE //
Source: https://www.businesswire.com/news/home/20260310728713/en/TerSera-Therapeutics-Announces-Closing-of-Divestiture-of-Infusion-Specialty-Therapies-Business-Unit-to-ESTEVE